At APSL, we have a highly skilled scientific team with expertise in variety of dosage forms like OSDs, injectable and topicals. At our state-of-the-art facility, we handle complex oral solid dosage forms, oral liquids, and parenteral dosage forms like aqueous liquid injectables, non-aqueous liquid injectables, lyophilized injectables and ophthalmic solutions. We specialize in pediatric dosage forms, fixed dose combinations and modified-release dosage forms. We also support for development of customized formulations for animals. Our expert team is having extensive experience in developing complex formulations and provide tailored solutions to your problems and help to optimize the development time and cost.
Our team is committed to delivering quality results in a time-bound and cost-effective manner at each stage of the development process. We also evaluate container closure systems, storage and transportation conditions.
ICH-compliant stability studies along with a range of conditions to cover various climatic zones across the globe, help in making decisions early in the drug development cycle.
With decades of experience in formulation development, our scientists look forward to accelerating the time to market of your molecule.
Our range of formulation dosage forms includes
Solid Orals
- Immediate-release tablets (chewable tablets, orally disintegrating tablets, sublingual tablets and bi-layer tablets)
- Modified release tablets (Monolayer, bilayer and mini tablets)
- Fixed dose combinations (Monolayer, Bilayer and Multi particulate systems (Granules, pellets or mini-tablets and combinations there off in capsule)
- Hard Capsules (Hard gelatin or HPMC capsules with powder in capsule, pellets in capsules and soft gelatin capsules)
- Multiparticulate systems (Pellets and mini tablets)
- Powder in sachet for solution/suspension
Oral Liquids
- Oral solutions with dosing cup
- Oral drops with dosing device
- Oral suspension
- Oral emulsions
Parenterals
- Aqueous liquid injectables
- Non-aqueous liquid injectables
- Lyophilized injectables
- Ophthalmic and otic solutions
- Nasal solutions (drops to be instilled into nostrils)
Topical
- Ointment
- Cream
- Gel
Why Aurigene Pharmaceutical Services?
Services across the product lifecycle
USFDA inspected lab and manufacturing facilities
Experience with advanced formulation technologies
20+ years of experience in formulation
Other Services
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Resources
FEBRUARY 25, 2025
Transforming Drug Discovery with Aurigene.AI
In the early 2000s, developing Sovaldi, a hepatitis C treatment, took over a decade and nearly $2 billion. Similarly, Zolgensma, a gene therapy for spinal muscular atrophy, required 15 years due to its complexity. However, the advent of artificial intelligence (AI) has revolutionized drug discovery. For example, in 2022, Pfizer's PAXLOVID, an oral COVID...
Read More
Advancement in personalized medicine and how the CRDMO industry is part of the solution
Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...
Read More
Cell Line Development
We enable development of stable and high yielding recombinant Mammalian and Microbial lines. ...
Read More
Familiarization, process optimization, and cGMP manufacturing and supply of 30.0 kg of a Bioactive Nucleotide (NAD Booster)
Background: A US-based biopharmaceutical company approached Aurigene Pharmaceutical Services for the familiarization, process development, and cGMP manufacturing and supply of 30.0 kg Nucleotide product (NAD booster) for phase-appropriate studies. The synthesis of the desired product involves three linear stages, which starts with reaction of a pentose...
Read More
Identification of Degradants of Thermal and Oxidation Stress Studies of Empagliflozin and Linagliptin Tablets by HPLC-PDA and LC-MS Instrumental Techniques
2022
Objective of the manuscript is to identify the degradants observed in the thermal and oxidation degradation sample of Empagliflozin and Linagliptin tablets by using LC-MS and HPLC-PDA instrumental techniques. Thermal and oxidation degradation samples were injected in HPLC-PDA and LC-MS instruments. Mass of the degradants were detected by LC-MS technique, ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Wang-OSO3H catalyzed green synthesis of bioactive isoindolo[2,1- a ]quinazoline-5,11–dione derivatives: An unexpected observation
2005
The sulphonic acid-functionalized Wang resin (Wang-OSO3H) was explored as a polymeric and recov- erable acidic catalyst for the synthesis of isoindolo[2,1- a ]quinazoline-5,11–dione derivatives under green conditions. Thus the Wang-OSO3H ...
Read More -
Polycyclic Aromatic Compounds: A Simple and Efficient [(n-Bu3Sn)2MO4]n Catalyzed Synthesis of Quinazolinones and Dihydroquinazolinones
2005
A novel unprecedented approach for the synthesis of various quinazolinones and dihydroquinazolinones has been using [(n-Bu3Sn)2MO4]n as a catalyst. The reaction has been screened ...
Read More
Frequently asked questions
What is formulation research and development?
Formulation development is a part of the drug product development process where the drug substance is combined with suitable excipients and processed to produce stable drug products such as tablets, capsules, injectables, topical cream/gel.
What is the role of formulations in pharmaceutics?
The formulation in pharmaceuticals is a process where the drug substance/API is mixed with an excipient to form a final drug product by considering the particle size, pH, stability, polymorphism, and solubility. It helps to decide the most optimal delivery mode such as oral, parenteral, pulmonary, nasal, topical, ophthalmic or rectal.
What does drug formulation mean?
Drug formulation is the process where a drug substance/ Active Pharmaceutical Ingredient (API) is converted into a final human consumable oral, parenteral, pulmonary, nasal, topical, ophthalmic, or rectal formulation to treat diseases.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market